I agree that Veru's earnings would be a business advantage however Don should stop making claims that RVX is going to get things done until they are actually ready to take their shots. I agree that the science at Veru is not necessarily better but we won't know wrt covid until if and when RVX actually completes the trial. With the previous proteomic analysis on Apabetalone and the way it tends to bring a number of proteins back towards normal expression I would think there is a chance it could be a preferable drug IF it works on covid. 

Way too much unsupported talking by management is probably, along with lousy financial management, one of the main reasons that a ph3 company with a BTD for its lead potentially blockbuster drug has a market cap which is far less than a number of pre-clinical biotechs and many multiples lower than what management said the EV was (about $4BUSD) post BETOnMACE. The shoddy performance of management is also probably why this company with cutting edge science has no first rate analyst coverage.

I agree that seeing a new experienced biotech CEO taking the reins would be a a great day, doubt it will ever happen. JMO